Madrigal Pharmaceuticals Surges as FDA Approves Liver Disease Treatment

By
Adriana Rossetti
1 min read
⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).

Madrigal Pharmaceuticals experienced a significant surge in stock value after the FDA authorized its groundbreaking treatment for fatty liver disease. The medication, resmetirom (Rezdiffra), was approved for noncirrhotic non-alcoholic steatohepatitis (NASH), a prevalent and severe fatty liver disease. The analysts at Jefferies estimate a peak sales potential of $3.4 billion in the U.S. and European Union. The biotech company's shares soared by over 250% in 2022 following positive trial results for the drug.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings

We use cookies on our website to enable certain functions, to provide more relevant information to you and to optimize your experience on our website. Further information can be found in our Privacy Policy and our Terms of Service . Mandatory information can be found in the legal notice